James G. Smith, who joined Applied Immune Sciences Inc.(NASDAQ:AISX) in September as senior vice president, has beennamed to the additional post of chief operating officer. TheMenlo Park, Calif., company is conducting clinical trials on celltherapy devices.
John J. Moulds, chief operating officer and vice president ofGamma Biologicals Inc., was named president of the Houston-based company. Gamma (ASE:GBL) manufactures and marketsdiagnostic reagents and biotech instruments.
Kevin M. Crowley has been named vice president of medicalproducts at Epitope Inc. of Beaverton, Ore. He was vicepresident of sales and marketing at Pharmacia Diagnostics Inc.Epitope (ASE:EPT) is developing diagnostic tests for AIDS andother indications, therapeutic anti-protozoal drugs and, throughits agricultural subsidiary, Agritope Inc., new plant varieties.
Immune Response Corp. appointed Steven W. Brostoff vicepresident of research and development, Fred C. Jensen vicepresident of virology research and development, and Steven P.Richieri vice president of medical and regulatory affairs. Theywere previously executive directors. The San Diego company(NASDAQ:IMNR) is focused on treatments for majorautoimmune diseases.
Cambridge NeuroScience Inc. elected to its board of directorsPaul O'Brien, CEO and president of New England Telephone, andIra Jackson, senior vice president of external affairs andmarketing of the Bank of Boston. The Cambridge, Mass.,company (NASDAQ:CNSI) is developing products to treatneurological and psychiatric disorders.
Celtrix Pharmaceuticals Inc. of Santa Clara, Calif., named StevenC. Leung director of quality control. Leung was manager ofquality control for the Hyland Division of Baxter HealthcareCorp. Celtrix (NASDAQ:CTRX) is engaged in the research anddevelopment of potential therapies for diseases associated withaging and autoimmune conditions.
Medtronic Inc. (NYSE:MDT) named Bill K. Erickson president ofits U.S. cardiovascular sales and marketing division. He is alsocorporate senior vice president. The Minneapolis companydevelops and manufactures biomedical devices for improvingcardiovascular and neurological health.
BioTechnica International Inc. of Overland Park, Kan., named toits board of directors William C. Hittinger, former executivevice president of RCA Corp., and Garvin C. Matthiesen, formersenior vice president of Farmland Industries Inc. BioTechnica(NASDAQ:BIOT) is engaged in the production and marketing ofagricultural seed products.
Gilead Sciences Inc. named Linda A. Fitzpatrick director ofinvestor relations and human resources. She was director ofinvestor relations at Genentech Inc. Foster City, Calif.-basedGilead (NASDAQ:GILD) focuses on pharmaceuticals based onnucleotides.
Leslie S. Casey was named senior scientist at CistronBiotechnology Inc. She was an advanced post-doctoral fellow atthe Harvard School of Public Health. The Pine Brook, N.J.,company is focused on immune system regulators.
MacroNex Inc., a drug discovery and development companybased near Research Triangle Park, N.C., named Henry Wongsenior scientist. He was a staff fellow in the cellularimmunology section of the National Institute of Dental Researchof the NIH.
Cel-Sci Corp. named Nicola M. Kouttab to its scientific advisoryboard. He is director of clinical immunology at Roger WilliamsMedical Hospital of Providence, R.I., and associate professor ofpathology at Brown University. The Alexandria, Va., company(NASDAQ:CELI) is developing lymphokine and cytokinemixtures for treating cancers and immunodeficiencies.
Hamilton Smith, Nobel laureate and professor at Johns HopkinsSchool of Medicine, was named to the scientific advisory boardof BioCryst Pharmaceuticals Inc. Smith received the 1978 NobelPrize in medicine. The Birmingham, Ala., company is focused onthe use of structure-based drug design.
(c) 1997 American Health Consultants. All rights reserved.